MA50189A - Formulations pharmaceutiques d'oligomère cyclique et d'abiratérone et procédés de formation et d'administration de celles-ci - Google Patents

Formulations pharmaceutiques d'oligomère cyclique et d'abiratérone et procédés de formation et d'administration de celles-ci

Info

Publication number
MA50189A
MA50189A MA050189A MA50189A MA50189A MA 50189 A MA50189 A MA 50189A MA 050189 A MA050189 A MA 050189A MA 50189 A MA50189 A MA 50189A MA 50189 A MA50189 A MA 50189A
Authority
MA
Morocco
Prior art keywords
abiraterone
administering
processes
forming
same
Prior art date
Application number
MA050189A
Other languages
English (en)
Inventor
Urvi Gala
Dave Miller
Original Assignee
Dispersol Technologies Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dispersol Technologies Llc filed Critical Dispersol Technologies Llc
Publication of MA50189A publication Critical patent/MA50189A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA050189A 2017-09-22 2018-09-20 Formulations pharmaceutiques d'oligomère cyclique et d'abiratérone et procédés de formation et d'administration de celles-ci MA50189A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762562081P 2017-09-22 2017-09-22

Publications (1)

Publication Number Publication Date
MA50189A true MA50189A (fr) 2021-05-19

Family

ID=65808544

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050189A MA50189A (fr) 2017-09-22 2018-09-20 Formulations pharmaceutiques d'oligomère cyclique et d'abiratérone et procédés de formation et d'administration de celles-ci

Country Status (10)

Country Link
US (1) US20190091339A1 (fr)
EP (1) EP3684371A4 (fr)
JP (2) JP2020534320A (fr)
KR (1) KR20200064993A (fr)
CN (1) CN111107852A (fr)
AU (1) AU2018335391A1 (fr)
CA (1) CA3075095A1 (fr)
IL (1) IL273125A (fr)
MA (1) MA50189A (fr)
WO (1) WO2019060525A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113825514A (zh) * 2019-03-18 2021-12-21 分散技术有限责任公司 阿比特龙-环状寡聚体药物制剂及其形成和施用方法
CN110141556B (zh) * 2019-06-24 2021-07-13 李建恒 一种阿比特龙包合物片剂及其制备方法
WO2021086565A1 (fr) * 2019-11-01 2021-05-06 Dispersol Technologies, Llc Formulations pharmaceutiques faiblement basiques de médicament et de polymère ionique et procédés de formation et d'administration de celles-ci
CA3160834C (fr) 2019-11-14 2024-06-11 Suven Life Sciences Limited Compositions pharmaceutiques amorphes d'acetate d'abiraterone
WO2021108022A1 (fr) * 2019-11-30 2021-06-03 Dispersol Technologies, Llc Complexes d'inclusion associant des produits pharmaceutiques et des oligomères cycliques
KR102363026B1 (ko) * 2019-12-26 2022-02-16 보령제약 주식회사 아비라테론 아세테이트 또는 이의 약제학적으로 허용 가능한 염을 포함하는 전립선암 예방 또는 치료용 약학적 조성물
IL303390A (en) 2020-12-03 2023-08-01 Battelle Memorial Institute Compositions of polymer nanoparticles and DNA nanostructures and methods for non-viral transport
WO2022216977A1 (fr) 2021-04-07 2022-10-13 Batelle Memorial Institute Technologies de conception, de construction, de test et d'apprentissage rapides pour identifier et utiliser des vecteurs non viraux
WO2025072751A1 (fr) 2023-09-29 2025-04-03 Battelle Memorial Institute Compositions de nanoparticules polymères pour l'expression in vivo de polypeptides
AU2024393766A1 (en) 2023-12-08 2026-06-18 Battelle Memorial Institute Use of dna origami nanostructures for molecular information based data storage systems

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009026461A2 (fr) * 2007-08-21 2009-02-26 Board Of Regents, The University Of Texas System Mélange thermocinétique pour des applications pharmaceutiques
US9040080B2 (en) * 2008-10-21 2015-05-26 Southwest Research Institute Processing of heat-sensitive active agents
JP2014523445A (ja) * 2011-07-18 2014-09-11 トーカイ ファーマシューティカルズ,インク. 前立腺癌を処置するための新規な組成物及び方法
MX367640B (es) * 2011-11-30 2019-08-29 Astrazeneca Ab Tratamiento combinado del cáncer.
GB201207886D0 (en) * 2012-05-04 2012-06-20 Jagotec Ag Improvements in or relating to organic compounds
WO2014009437A1 (fr) * 2012-07-11 2014-01-16 Sandoz Ag Stabilité d'oxydation d'acétate d'abiratérone
TWI686212B (zh) * 2013-03-15 2020-03-01 阿聯商太陽法瑪全球有限公司 醋酸阿比特龍配方
WO2015032873A1 (fr) * 2013-09-06 2015-03-12 Synthon B.V. Compositions pharmaceutiques à charge élevée comprenant de l'acétate d'abiratérone
EP3201191A1 (fr) * 2014-10-01 2017-08-09 Mylan Laboratories Ltd. Complexe d'empagliflozine amorphe et d'une cyclodextrine
WO2017037647A1 (fr) * 2015-09-02 2017-03-09 Leiutis Pharmaceuticals Pvt Ltd Compositions pharmaceutiques stables d'abiratérone

Also Published As

Publication number Publication date
JP2020534320A (ja) 2020-11-26
KR20200064993A (ko) 2020-06-08
AU2018335391A1 (en) 2020-03-26
EP3684371A1 (fr) 2020-07-29
US20190091339A1 (en) 2019-03-28
WO2019060525A1 (fr) 2019-03-28
CN111107852A (zh) 2020-05-05
CA3075095A1 (fr) 2019-03-28
JP2023182674A (ja) 2023-12-26
EP3684371A4 (fr) 2021-05-19
IL273125A (en) 2020-04-30

Similar Documents

Publication Publication Date Title
EP3684371A4 (fr) Formulations pharmaceutiques d'oligomère cyclique et d'abiratérone et procédés de formation et d'administration de celles-ci
IL275704A (en) Pharmaceutical formulation for oral administration containing cannabinoids and poloxamer
EP3356522A4 (fr) Compositions contenant un exosome chargé d'une protéine, et procédés de préparation et d'administration correspondants
EA201791702A1 (ru) Терапевтические средства на основе гликанов и связанные с ними способы
EP3946547A4 (fr) Dispositifs et procédés d'administration de compositions pharmaceutiques
MA52257A (fr) Compositions pharmaceutiques comprenant blautia et leur administration orale
IL284733A (en) Pharmaceutical delivery compositions and uses thereof
SV2017005601A (es) Formulaciones farmacéuticas que contienen tenofovir y emtricitabina
MX387731B (es) Composiciones farmacéuticas orales de mesalazina.
EP3380525A4 (fr) Formulations pharmaceutiques et leurs procédés d'utilisation
EP3643353A4 (fr) Robot d'administration de médicament
EP3773900A4 (fr) Analogues d'hinokitiol, procédés de préparation et compositions pharmaceutiques de ceux-ci
EP3528787A4 (fr) Formulations pharmaceutiques et leurs procédés de préparation
EP3442542A4 (fr) Nanoparticules, formes posologiques à libération contrôlée et procédés d'administration d'un agent immunothérapeutique
EP3318282A4 (fr) Vecteur d'administration de médicament, et composition le contenant
MA41326A (fr) Formulations pharmaceutiques comprenant du cangrelor de haute pureté et leurs procédés de préparation et d'utilisation
EP3526195A4 (fr) Sulfoxyalkyle organonitro, composés apparentés et compositions pharmaceutiques destinées à être utilisées en médecine
EP3694590A4 (fr) Systèmes d'administration de médicaments et procédés associés
MA55015A (fr) Formulations pharmaceutiques
EP3773654C0 (fr) Compositions médicamenteuses polypharmaceutiques et méthodes associées
EP3982942A4 (fr) Procédés et compositions d'administration de médicament
EP3377043A4 (fr) Véhicules nanométriques déformables (dnvs) pour l'administration transmucosale et transdermique de médicaments à travers la barrière hémato-encéphalique
EP3452441A4 (fr) Dérivés d'acide alpha-truxillique et compositions pharmaceutiques associées
EP3613742A4 (fr) Dérivés d'indolizine et leur application en médecine
EP3801539A4 (fr) Compositoins pharmaceutiques solides d'administration par voie orale comprenant de la linagliptine